


# Results

## First Quarter 2012/13

Investor Call  
Mannheim, 27<sup>th</sup> June 2012



Dr. Michael Majerus  
CFO



© 2012 PHOENIX Pharmahandel GmbH & Co KG

This document has been prepared by PHOENIX Pharmahandel GmbH & Co KG (the “Company” and, together with its subsidiaries and affiliates, “PHOENIX”) solely in connection with the release of the results of the first quarter 2012/13 and is being presented solely for informational purposes. No representation or warranty, express or implied, is or will be made in relation to, and no responsibility is or will be accepted by the Company or any of its respective affiliates, advisors or representatives (together, the “Parties”) as to the accuracy or completeness of the information contained in this document, and nothing in this document shall be deemed to constitute such a representation or warranty. None of the Parties or their respective agents, directors, partners and employees accept any liability whatsoever (in negligence or otherwise) for any loss or damage howsoever arising from any use of this document or its contents or otherwise arising in connection therewith and no reliance should be placed on the information or statements made herein.

This document does not constitute or form part of and should not be construed as a recommendation, offer or invitation for the purchase or subscription of any securities of the Company or any subsidiary, and neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever.

The information contained in this presentation has not been subject to any independent audit or review. A portion of the information contained in this document, including all market data and trend information, is based on estimates or expectations of the Company, and there can be no assurance that these estimates or expectations are or will prove to be accurate. In addition, past performance of PHOENIX is not indicative of future performance. The future performance of PHOENIX will depend on numerous factors which are subject to uncertainty.

Certain statements contained in this presentation that are not statements of historical fact, including, without limitation, any statements preceded by, followed by or including the words “targets,” “believes,” “expects,” “aims,” “intends,” “may,” “anticipates,” “would,” “could” or similar expressions or the negative thereof, constitute forward-looking statements, notwithstanding that such statements are not specifically identified. In addition, certain statements may be contained in press releases, and in oral and written statements made by or with the approval of the Company that are not statements of historical fact and constitute forward-looking statements. Examples of forward-looking statements include, but are not limited to: (i) statements about future financial and operating results; (ii) statements of strategic objectives, business prospects, future financial condition, budgets, projected levels of production, projected costs and projected levels of revenues and profits of the Company or its management; (iii) statements of future economic performance; and (iv) statements of assumptions underlying such statements.

Forward-looking statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions which are difficult to predict and outside of the control of the management of the Company. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. You should not place undue reliance on these forward-looking statements. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements referenced above. Forward-looking statements speak only as of the date on which such statements are made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement to reflect events or circumstances after the date on which such statement is made, or to reflect the occurrence of unanticipated events.

## Stable business development

- Based on a stable business development in Q1 2012/13, PHOENIX once more confirmed its **position as leading pharmaceutical distributor across Europe**
- **Turnover** is influenced by the **flat development of the pharmaceutical markets**
- **Gross profit in percent of net turnover increased** from 8.99% in the previous year's 1<sup>st</sup> quarter to **9.65% in Q1 2012/13**
- When adjusted for the **dissolution of accrued transaction costs (EUR 18.4m) due to the premature refinancing**, the **profit for the period is slightly above the level of the prior year's first quarter**
- **Investments into fixed assets** are made primarily in order to **further optimize the PHOENIX distribution network** and to **further enhance the attractiveness of our retail shops** across Europe
- In retail, the **rebranding to BENU** has successfully started

# Despite increasing market pressure, PHOENIX shows growth in gross profit



## Revenue

## Gross Profit


## EBITDA

## Profit for the period

(after tax, before minorities)

▨ Q1 2012/13 adjusted for premature dissolution of accrued transaction costs

(m€)



## Sound group financing

- On **21 June 2012**, PHOENIX concluded a **EUR 1.35bn syndicated facilities agreement** with 15 German and international banks
- The **maturity of the new facility** is **four years** (term loan; EUR 300m) and **five years** (revolving credit facility; EUR 1.05bn), respectively
- The **existing syndicated facilities agreement from 2010** (originally EUR 2.6bn; reduced to EUR 1.485bn) will be **prematurely redeemed**
- Thanks to the new agreement, **PHOENIX group further enhanced its entrepreneurial freedom**
- The **successful refinancing** was strongly supported by **PHOENIX group's attractive business model** and the **consequent reduction of indebtedness in recent years**
- PHOENIX group has a **well-diversified corporate financing structure**
- Both **Standard & Poor's** as well as **FitchRatings** have published **company ratings of BB with stable outlook** for PHOENIX

Despite the challenging market environment, the P&L shows an improved gross profit and adjusted profit for the period

Profit & Loss (in m€)	Q1 2011/12	Q1 2012/13	Share of net turnover	Delta in %
<b>Net turnover</b>	<b>5,397</b>	<b>5,197</b>	<b>100%</b>	<b>-3.7%</b>
Cost of goods sold	-4,912	-4,696	-90.3%	-4.4%
<b>Gross profit</b>	<b>485</b>	<b>502</b>	<b>9.7%</b>	<b>3.4%</b>
Other income	37	39	0.7%	5.0%
Personnel expenses	-251	-267	-5.1%	6.3%
Other operative expenses	-135	-144	-2.8%	6.3%
Result from associates and other invest.	0	0	0.0%	1.7%
<b>EBITDA</b>	<b>136</b>	<b>130</b>	<b>2.5%</b>	<b>-4.4%</b>
Depreciation	-23	-25	-0.5%	5.7%
Financial result	-36	-51	-1.0%	41.7%
<b>Profit before taxes</b>	<b>77</b>	<b>55</b>	<b>1.1%</b>	<b>-28.8%</b>
Income taxes total	-24	-16	-0.3%	-32.4%
<b>Profit for the period</b>	<b>54</b>	<b>39</b>	<b>0.8%</b>	<b>-27.3%</b>
<b>Adjusted profit for the period*</b>	<b>54</b>	<b>55</b>	<b>1.1%</b>	<b>1.9%</b>

## Developments

- Despite turnover reduction, **gross profit improved** as a result of margin-oriented sales policy, additional higher-margin revenue, and the increasing share of retail business
- Gross profit improvement does not allow to fully compensate **increased personnel costs** (+15.8 m€ vs. PY) and **other costs** (+8.5 m€ vs. PY) due to normal progression of wages and transport costs, but also due to pharmacy acquisitions within Norway and the Netherlands, as well as wholesale acquisitions in Italy
- The **financial result** is influenced by the early refinancing of PHOENIX group and the corresponding one-time effect of the dissolution of transaction costs (-18.4 m€). Excluding these costs, the financial result has improved thanks to the reduced net debt and better financing conditions
- Tax rate** is also improved from 30.5% to 29.0%
- In consequence, the **adjusted profit for the period** is slightly above the level of the prior year's first quarter

\* Adjusted for the dissolution of accrued transaction costs due to premature refinancing

# PHOENIX group's optimized financial structure improves the interest result



Financial result (in m€)	Q1 2011/12	Q1 2012/13	Delta
Interest income	7.8	6.3	-1.5
Interest expenses	-44.0	-38.3	5.7
<b>Interest result</b>	<b>-36.2</b>	<b>-32.0</b>	<b>4.2</b>
Dissolution of transaction cost due to premature refinancing	0.0	-18.4	-18.4
Other net financial result*	0.5	-0.2	-0.7
<b>Financial result</b>	<b>-35.7</b>	<b>-50.6</b>	<b>-14.9</b>

## Developments


- Reduction of interest income due to lower interest from customers
- Lower interest expenses are mainly driven by reduced debt and optimized interest rates
- Most influencing factor is the premature refinancing of PHOENIX group, resulting in the dissolution of corresponding transactional cost

\* Other net financial result comprises

- “other financial income and expenses“,
- “financial income and expenses from derivatives” as well as
- “exchange rate gains and losses” related to the financial result

# PHOENIX continues its committed path of strengthening its balance sheet

(m€)



## Developments

- Financial liabilities slightly increase due to seasonally higher net working capital
- Equity ratio further improved by profit for the period and reduced balance sheet total
- Slight growth in inventories due to seasonal effects
- Trade receivables and also trade payables decreased due to lower turnover
- Overall, despite absolute increase of NWC (+138 m€), on average NWC days are still lower than previous Q1 and year end:
  - NWC days Q1 2011/12: 40.0
  - NWC days YE 2011/12: 39.9
  - NWC days Q1 2012/13: 38.6

- Financial Liabilities
- Cash & Equivalents
- Equity
- Net Working Capital
- Other


Balance ratio



# Net Debt has significantly improved compared to previous year

(m€)


04/30/2012



## Developments

- Reclassification of SFA within current financial liabilities
- Net Debt reduction of 335 m€ compared to Q1 2011/12:
  - Reduction of net financial liabilities by 305 m€
  - Reduction of ABS/factoring by 35 m€

04/30/2011




# The renewal of the syndicated bank facilities improves the maturity profile

## Financial facilities and headroom


(m€)

04/30/2012




- Diversified financing structure
- Significant financial headroom and efficient utilisation of cash allowed reduction of credit lines

## Debt maturity profile



- Renewal of SFA extends the duration and better distributes the maturities

# The active management of net working capital shows significant improvements




## Key Achievements

- Slight increase in stock (due to acquisitions in Italy)
- Decrease of trade receivables due to lower turnover, but also ongoing local optimization
- Payables absolutely decreased (lower turnover), day wise significantly improved
- Overall, significantly improved NWC

• Balance sheet figures as externally reported  
 • Net working capital days: Average figures for the respective period; figures including ABS/factoring; may include rounding differences


# The cash flow for the first quarter shows a negative free cash flow – as expected due to seasonal swings



## Cash flow development

- Lower profit for the period due to increased operational costs and increased negative financial results by dissolution of transaction costs due to premature refinancing
- Second column is especially higher due to effect of transaction costs
- Seasonal increase in net working capital, but substantially improved compared to previous year
- Cash flow from investing activities on normal level, slightly increased due to investments in fixed assets
- Free cash flow negative - as expected - but on a better level than previous year

## Typical seasonal cash flow swings by PHOENIX (example FY 2011/12)




# Summary: Development of key credit indicators

	01/31/2012	04/30/2012	Delta in %
Equity (in m€)	1,935.6	1,970.2	1.8%
Equity Ratio	26.1%	27.0%	3.3%
Net Debt (in m€)	1,855.7	2,050.4	10.5%
Gearing (Net Debt/Equity)	95.9%	104.1%	8.6%
	Q1 2011/12	Q1 2012/13	Delta in %
EBITDA (in m€)	136.3	130.3	-4.4%
EBITDA-Margin	2.5%	2.5%	-0.7%
Adjusted EBITDA* (in m€)	143.8	136.5	-5.1%
Adj.-EBITDA-Margin*	2.7%	2.6%	-7.1%
Net Debt / Adjusted EBITDA* (LTM)	3.89	3.67	-7.3%
Interest Coverage Ratio (EBIT / Interest Expenses)	2.6	2.8	7.5%
Profit before tax (in m€)	77.2	54.9	-28.8%
PBT-Margin	1.4%	1.1%	-26.1%
Profit after tax (in m€)	53.7	39.0	-27.3%
PAT-Margin	1.0%	0.8%	-24.5%
Adjusted profit after tax (in m€)**	53.7	54.5	1.6%
Adjusted PAT-Margin	1.0%	1.0%	5.5%

\* Adjusted EBITDA according to Bond definition  
LTM = Last twelve months


\*\* Adjusted for the dissolution of accrued transaction costs  
due to premature refinancing

After a decrease in fall 2011, the price of the PHOENIX bond is now back at approx. 110% of the nominal value



till 06/26/2012

# The good performance of the PHOENIX bond starting Oct' 11 is shown by the spread to the high yield index



\* Yield to maturity minus swap rate

# PHOENIX group with unchanged stringent financial policy

## Deleveraging strategy


- Further deleveraging is integral part of PHOENIX's financial policy and is backed by its main shareholders
- Net Debt/EBITDA target of around 3.0x
- PHOENIX is confident to reach its leverage target in the next two years

## Carefully managed acquisition activity

- PHOENIX's growth strategy is focused on above market organic growth
- Profitable and financially sound add-on acquisitions (mainly pharmacies) may also be pursued, but only within a predefined acquisition budget



Reporting Event	Date
1 <sup>st</sup> Half-Year Results	09/27/2012
3 <sup>rd</sup> Quarter Results	12/20/2012



**PHOENIX** group